Get to know our clinical trials

Study of ro7300490,alone or in combination with atezolizumab, in participants with advanced and/or metastatic solid tumors.

THE PURPOSE OF THIS STUDY IS TO EVALUATE THE SAFETY OF DIFFERENT DOSE LEVELS OF RO7300490, ALONE OR IN COMBINATION WITH A FIXED DOSE OF THE ANTICANCER DRUG ATEZOLIZUMAB (TECENTRIQ¿Μ), AND TO SEE WHAT EFFECTS, GOOD OR BAD, RO7300490, ALONE OR IN COMBINATION WITH ATEZOLIZUMAB, HAS ON YOU AND YOUR CANCER.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE I, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF RO7300490, A CD40 AGONIST DIRECTED AGAINST FIBROBLAST ACTIVATION PROTEIN (FAP), ALONE OR IN COMBINATION WITH ATEZOLIZUMAB, IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS.
  • Code EudraCT: 2020-004489-21
  • Protocol number: WP42627
  • Promoter: Roche Farma, S.A.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.